Code of Federal Regulations (Last Updated: November 8, 2024) |
Title 42 - Public Health |
Chapter IV - Centers for Medicare & Medicaid Services, Department of Health and Human Services |
SubChapter C - Medical Assistance Programs |
Part 447 - Payments for Services |
Subpart F - Payment Methods for Other Institutional and Noninstitutional Services |
Drugs |
§ 447.331 - Drugs: Aggregate upper limits of payment.
-
(a)
Multiple source drugs. Except for brand name drugs that are certified in accordance with paragraph (c) of this section, the agency payment for multiple source drugs must not exceed, the amount that would result from the application of the specific limits established in accordance with § 447.332. If a specific limit has not been established under § 447.332, then the rule for “other drugs” set forth in paragraph (b) applies.(b)
Other drugs. The agency payments for brand name drugs certified in accordance with paragraph (c) of this section and drugs other than multiple source drugs for which a specific limit has been established under § 447.332 must not exceed in the aggregate, payment levels that the agency has determined by applying the lower of the—(1) Estimated acquisition costs plus reasonable dispensing fees established by the agency; or
(2) Providers’ usual and customary charges to the general public.
(c)
Certification of brand name drugs. (1) The upper limit for payment for multiple source drugs for which a specific limit has been established under § 447.332 does not apply if a physiciancertifies in his or her own handwriting that a specific brand is medically necessary for a particular recipient. (2) The agency must decide what certification form and procedure are used.
(3) A checkoff box on a form is not acceptable but a notation like “brand necessary” is allowable.
(4) The agency may allow providers to keep the certification forms if the forms will be available for inspection by the agency or HHS.